Rhumbline Advisers Purchases 10,805 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Rhumbline Advisers raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 323,769 shares of the biopharmaceutical company’s stock after purchasing an additional 10,805 shares during the period. Rhumbline Advisers owned approximately 0.27% of Catalyst Pharmaceuticals worth $5,015,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 819 shares during the period. CWM LLC increased its holdings in shares of Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 3,549 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter valued at about $154,000. Ameritas Investment Partners Inc. grew its position in shares of Catalyst Pharmaceuticals by 6.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 720 shares during the period. Finally, Virtu Financial LLC bought a new stake in Catalyst Pharmaceuticals during the 1st quarter worth approximately $191,000. 79.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on CPRX shares. HC Wainwright lifted their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Citigroup increased their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Oppenheimer restated an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Truist Financial increased their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $29.50.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now owns 12,369 shares in the company, valued at $227,836.98. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Steve Miller sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 201,058 shares of company stock worth $4,018,188. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 0.3 %

Shares of CPRX opened at $20.22 on Monday. The company’s fifty day simple moving average is $18.42 and its 200 day simple moving average is $16.66. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.55 and a 1-year high of $20.87. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 37.44, a PEG ratio of 3.10 and a beta of 0.75.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. As a group, research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.